Moneycontrol PRO
HomeNewsMedical technology association of india

Medical Technology Association Of India

Jump to
  • Budget 2024: MTaI seeks lowering of customs duty, removal of health cess on medical devices

    The Medical Technology Association of India on January 17 sought the lowering of customs duty to 2.5 percent and the removal of health cess ad valorem on medical devices in the upcoming Union Budget.

  • Budget 2023: Medical device makers seek GST cut to battle imports from China, US

    Demand help for MSMEs in the sector, higher import duty, increase in healthcare expenditure and restructuring of GST rates to encourage the domestic industry against imports which grew 41 per cent last year.

  • Medical device industry suffers up to 85% drop in revenues during Apr-June: Medical Technology Association of India

    Medical Technology Association of India (MTaI), which represents research-based medical technology companies in the country, said the government should consider reducing tax burden on medical devices in order to revive the sector.

  • NPPA simplifies rules to ensure no stents shortage to patients

    NPPA said relabelling of stents is not mandatory, and called upon manufacturers and importers to issue revised price lists as quickly as possible in line with its price cap order - a move seen as an attempt to simplify the process ensure continuation of cardiac services to patients.

  • After pricing cap, NPPA warns of 'artificial' shortage of stents

    NPPA said the government can direct any manufacturer to maintain, import or increase supplies of cardiac stents in public interest, and a designated officer of government of both State and Central can enter, search and seize stocks of stents anywhere in the trade channel – if they found to be hoarding them.

  • NPPA justifies stent price cap, says cos can still make a profit

    The National Pharmaceutical Pricing Authority (NPPA) on Wednesday justifying its price ceiling indicated that it still left enough room for the stent makers to make a decent margin and the drug price control order (DPCO) has provision for separate prices for superior products – two main concerns raised by the stent manufacturers.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347